EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast

被引：3
作者：
Le, Xiuning [1 ]
Nadler, Eric [2 ]
Costa, Daniel B. [3 ]
Heymach, John Victor [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
来源：
TARGETED ONCOLOGY | 2023年 / 18卷 / 06期
关键词：
AFATINIB; OSIMERTINIB; NSCLC;
D O I：
10.1007/s11523-023-00994-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[media not available: see fulltext]
引用
收藏
页码：807 / 817
页数：11
相关论文
共 50 条
  • [21] Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
    Wang, Mengzhao
    Xu, Yan
    Huang, Wen-Tsung
    Su, Wu-Chou
    Gao, Bo
    Lee, Chee Khoon
    Fang, Jian
    Zhu, Xuehua
    Yang, Zhenfan
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    LUNG CANCER, 2025, 199
  • [22] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Giandomenico Roviello
    Laura Zanotti
    Maria Rosa Cappelletti
    Angela Gobbi
    Martina Dester
    Giovanni Paganini
    Chiara Pacifico
    Daniele Generali
    Raheleh Roudi
    Clinical and Experimental Medicine, 2018, 18 : 15 - 20
  • [23] Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer?
    Roviello, Giandomenico
    Zanotti, Laura
    Cappelletti, Maria Rosa
    Gobbi, Angela
    Dester, Martina
    Paganini, Giovanni
    Pacifico, Chiara
    Generali, Daniele
    Roudi, Raheleh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 18 (01) : 15 - 20
  • [24] The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer
    Arrieta, Oscar
    Felipe Cardona, Andres
    Corrales, Luis
    Delia Campos-Parra, Alma
    Sanchez-Reyes, Roberto
    Amieva-Rivera, Eduardo
    Rodriguez, July
    Vargas, Carlos
    Carranza, Hernan
    Otero, Jorge
    Karachaliou, Nikki
    Astudillo, Horacio
    Rosell, Rafael
    LUNG CANCER, 2015, 87 (02) : 169 - 175
  • [25] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
  • [26] EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges
    Tfayli, Arafat
    Mohty, Razan
    TUMORI JOURNAL, 2021, 107 (05): : 376 - 384
  • [27] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [28] Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X
    Yue Hao
    Manyi Xu
    Huan Zhou
    Jinfei Si
    Yu Fang
    Chunwei Xu
    Zhengbo Song
    Medical Oncology, 40
  • [29] Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells
    Katayama, Yuki
    Yamada, Tadaaki
    Tokuda, Shinsaku
    Okura, Naoko
    Nishioka, Naoya
    Morimoto, Kenji
    Tanimura, Keiko
    Morimoto, Yoshie
    Iwasaku, Masahiro
    Horinaka, Mano
    Sakai, Toshiyuki
    Kita, Kenji
    Yano, Seiji
    Takayama, Koichi
    CANCER MEDICINE, 2022, 11 (04): : 944 - 955
  • [30] An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
    Keunchil Park
    Jin-Soo Kim
    Joo-Hang Kim
    Young-Chul Kim
    Hoon-Gu Kim
    Eun Kyung Cho
    Jong-Youl Jin
    Miyoung Kim
    Angela Märten
    Jin-Hyoung Kang
    BMC Cancer, 21
12345